Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 83 of the 85 references it cites were found in a registry or an index, and 2 are not checked yet; 133 of the 242 sources its claims cite were checked for support.

The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review

Open access
Willmington, Claire, Kirby, Ann, Murphy, Aileen · 2025 · Health Economics Review

Abstract

BACKGROUND: Retinal disease is one of the leading causes of blindness and vision impairment worldwide, including Europe. With the advent of gene therapy, the treatment landscape for retinal disease is changing and clinical trials are underway investigating the therapeutic potential of gene therapy in both acquired and inherited retinal diseases. Given the high price of innovative medicines, it is essential to consider the current costs associated with retinal diseases to inform economic evaluations early in the life cycle of these forthcoming treatments. These could inform future reimbursement decisions, health budgets and service delivery plans. AIM: This systematic literature review sought to examine the economic burden of retinal diseases, for which gene therapy is emerging for patients in Europe. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guideline, a systematic search was performed using the Medline, CINAHL, EconLit and Embase databases. The searches were restricted to English language articles published after 1st January 2000. Following article selection, data were extracted in a tabular form and a narrative synthesis was performed. RESULTS: A total of 28 research studies were identified and included in the review that varied in terms of disease of interest, size, country setting, methodology, as well as how costs were reported and valued. While many retinal diseases were considered, almost half of the articles related to the costs of neovascular age-related macular degeneration (nAMD). Significant cost variations were observed across the studies as costs ranged from 45 USD to almost 30,000 USD per patient per annum, across all conditions combined. CONCLUSION: This systematic literature review evidences the heterogeneity among studies analysing the economics of retinal diseases underlying vision impairment. The paucity in the literature, signals the need for further research investigating the costs associated with retinal diseases, for which innovative therapies are expected to enter the market and will be subject to evaluation by decision-makers, whose decisions will have a significant impact on the delivery of these technologies to patients.

Verified 2026-10-05 · 2 references not checked yet

Overview

CoChat Summary

TL;DR

This systematic review identified 28 European studies on the economic burden of retinal diseases for which gene therapy is emerging, finding wide cost variation and substantial methodological heterogeneity. It concludes that evidence is sparse and often outdated, limiting economic evaluations of forthcoming gene therapies.

Key findings

  • The review included 28 studies; over half related to AMD (55%), followed by DR and DMO (31%), with RVO, mCNV and IRD combined accounting for 14%. Almost half of the articles related to nAMD.
  • Annual per-patient costs ranged from $45 to almost $30,000 across all conditions. Ranges were higher in nAMD ($228–$28,000) and DMO ($370–$28,000) than in dry AMD ($300–$3,000), DR without complications ($45–$4,000), and macular oedema secondary to RVO ($1,800–$12,000).
  • Direct medical costs were $228–$12,133 per patient per annum for nAMD and $370–$14,642 for DMO at patient level; NPDR direct medical costs were $45–$613 and PDR costs $441–$3,031.
  • Only one IRD study and one mCNV study were identified. The IRD study reported direct medical costs of $674 and direct non-medical costs of $241 per patient per year; the mCNV study reported direct medical costs of $3,859, direct non-medical costs of $498, and productivity loss of $7,976 per patient per annum.

Methods

  • PRISMA 2020 systematic review, registered in PROSPERO (CRD42024576511). Medline, CINAHL, EconLit and Embase were searched on 15 July 2024, restricted to English-language articles published after 1 January 2000 and studies conducted in the European region.
  • Inclusion was limited to partial economic evaluations (cost analyses and cost-of-illness studies); full economic evaluations, reviews, conference presentations, case reports, protocols and abstracts were excluded. From 5,270 initial records, 3,169 were screened after duplicates, 301 underwent full-text screening, and 28 met inclusion criteria.
  • Data were extracted in tabular form and narratively synthesised. Costs were inflated and converted to 2024 USD using the CCEMG–EPPI Centre Cost Converter; reporting quality was assessed with the British Medical Journal checklist for economic submissions and the CHEERS checklist.

Limitations

  • Stated by the authors: the geographical scope was restricted to Europe; patients were not distinguished by disease severity or laterality; overrepresentation of nAMD studies may have made retinal disease costs appear higher than they are; and the effects of differences between older-age diseases (e.g. AMD) and younger-onset diseases (e.g. DR and IRD) on costs were not examined.
  • Evident from the text: studies varied widely in disease of interest, sample size, country, methodology, cost components, perspective, time horizon, and how costs were reported and valued. Many nAMD studies used pre-2010 cost data and did not include anti-VEGF costs, so estimates may not reflect current practice.
  • Evident from the text: indirect costs were estimated in only 10 studies, informal care in 3, and intangible costs in 2; non-ophthalmological and non-medical resources were inconsistently included, potentially underestimating the true economic burden.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13561-025-00707-7

Cites

83 of 85 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Study selection
Fig. 1 Study selectionCC BY-NC-ND · PubMed Central
Fig. 2 Taxonomy of the economic burden of retinal disease
Fig. 2 Taxonomy of the economic burden of retinal diseaseCC BY-NC-ND · PubMed Central
Fig. 3 Total annual costs per person for nAMD across countries (in 2024 USD)
Fig. 3 Total annual costs per person for nAMD across countries (in 2024 USD)CC BY-NC-ND · PubMed Central
Fig. 4 Total annual costs per person for dry AMD across countries (in 2024 USD)
Fig. 4 Total annual costs per person for dry AMD across countries (in 2024 USD)CC BY-NC-ND · PubMed Central
Fig. 5 Total annual costs per person for NPDR and PDR across countries (in 2024 USD)
Fig. 5 Total annual costs per person for NPDR and PDR across countries (in 2024 USD)CC BY-NC-ND · PubMed Central
Fig. 6 Total annual costs per person for DMO across countries (in 2024 USD)
Fig. 6 Total annual costs per person for DMO across countries (in 2024 USD)CC BY-NC-ND · PubMed Central
Fig. 7 Total annual costs per person for IRD (in 2024 USD)
Fig. 7 Total annual costs per person for IRD (in 2024 USD)CC BY-NC-ND · PubMed Central
Fig. 8 Total annual costs per person for macular oedema secondary to RVO and mCNV across countries (in 2024 USD). a RVO. RVO: retinal vein occlusion. b mCNV. mCNV: myopic choroidal neovascularisation]
Fig. 8 Total annual costs per person for macular oedema secondary to RVO and mCNV across countries (in 2024 USD). a RVO. RVO: retinal vein occlusion. b mCNV. mCNV: myopic choroidal neovascularisation]CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

70 Valid · 6 Not valid · 31 Not checked · 56 Own results and interpretations

70 more claims · 34 with their cited sources checked

Create a free account to see all 163 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 40

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 83 references

Research works printed but not linked: 2

  1. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, Second Edition. American J Prev Med. 1998;14.
  2. European Commission. European Commission-Press release New EU rules on Health Technology Assessment open up a new era for patient access to innovation. 2025.

Metadata

Authors
Willmington, C., Kirby, A., & Murphy, A.
Affiliations
University College Cork (IE)
Corresponding author
Willmington, Claire
Venue
Health Economics Review
Published
2025-12-07
Volume
16
Issue
1
Pages
21-21
ISSN
2191-1991 (ISSN-L)
OpenAlex
W4417115362
Cited by
0
References
83
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • Health Economics Review (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Cork Open Research Archive (University College Cork, Ireland) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
European Union’s Horizon Europe (101073316)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
retinal disease, gene therapy, economic burden, health care costs, neovascular age-related macular degeneration, inherited retinal disease, visual impairment, cost heterogeneity, reimbursement decisions, innovative medicines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review. https://app.cochat.ai/papers/10.1186/s13561-025-00707-7
The paper
Willmington, C., Kirby, A., & Murphy, A. (2025). The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review. Health Economics Review. https://doi.org/10.1186/s13561-025-00707-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.